Perventricular device closure of congenital muscular ventricular septal defects

Carlos A.C. Pedra, Simone R.F. Pedra, Paulo Chaccur, Marcelo Jatene, Rodrigo N. Costa, Ziyad M. Hijazi, Zahid Amin

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Muscular ventricular septal defects (MVSDs) account for approximately 20% of all congenital ventricular septal defects. Large defects in infants result in early heart failure, failure to thrive and pulmonary hypertension. Although percutaneous closure of MVSDs has been employed safely and effectively in children, adolescents and adults, its application in the small infant (weight <6 kg) carries a higher risk for complications including arrhythmias, hemodynamic compromise, cardiac perforation, tamponade and death. Perventricular closure of such defects, introduced by Amin and coworkers in the late 1990s, has become an attractive treatment modality for these small and high-risk patients. Experience worldwide has shown that the procedure is feasible, reproducible, safe and effective. In this article, the authors review the indications, the step-by-step technique and the results of perventricular closure of MVSDs using the AMPLATZER® mVSD device (AGA Medical, MN, USA).

Original languageEnglish (US)
Pages (from-to)663-674
Number of pages12
JournalExpert Review of Cardiovascular Therapy
Volume8
Issue number5
DOIs
StatePublished - May 1 2010
Externally publishedYes

Fingerprint

Ventricular Heart Septal Defects
Equipment and Supplies
Failure to Thrive
Cardiac Tamponade
Pulmonary Hypertension
Cardiac Arrhythmias
Heart Failure
Hemodynamics
Weights and Measures
Therapeutics

Keywords

  • AMPLATZER
  • Hybrid
  • Interventional catheterization
  • Muscular ventricular septal defects
  • Perventricular

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Pedra, C. A. C., Pedra, S. R. F., Chaccur, P., Jatene, M., Costa, R. N., Hijazi, Z. M., & Amin, Z. (2010). Perventricular device closure of congenital muscular ventricular septal defects. Expert Review of Cardiovascular Therapy, 8(5), 663-674. https://doi.org/10.1586/erc.10.31

Perventricular device closure of congenital muscular ventricular septal defects. / Pedra, Carlos A.C.; Pedra, Simone R.F.; Chaccur, Paulo; Jatene, Marcelo; Costa, Rodrigo N.; Hijazi, Ziyad M.; Amin, Zahid.

In: Expert Review of Cardiovascular Therapy, Vol. 8, No. 5, 01.05.2010, p. 663-674.

Research output: Contribution to journalReview article

Pedra, CAC, Pedra, SRF, Chaccur, P, Jatene, M, Costa, RN, Hijazi, ZM & Amin, Z 2010, 'Perventricular device closure of congenital muscular ventricular septal defects', Expert Review of Cardiovascular Therapy, vol. 8, no. 5, pp. 663-674. https://doi.org/10.1586/erc.10.31
Pedra, Carlos A.C. ; Pedra, Simone R.F. ; Chaccur, Paulo ; Jatene, Marcelo ; Costa, Rodrigo N. ; Hijazi, Ziyad M. ; Amin, Zahid. / Perventricular device closure of congenital muscular ventricular septal defects. In: Expert Review of Cardiovascular Therapy. 2010 ; Vol. 8, No. 5. pp. 663-674.
@article{382736313cfe4d93a130c819bb209ecb,
title = "Perventricular device closure of congenital muscular ventricular septal defects",
abstract = "Muscular ventricular septal defects (MVSDs) account for approximately 20{\%} of all congenital ventricular septal defects. Large defects in infants result in early heart failure, failure to thrive and pulmonary hypertension. Although percutaneous closure of MVSDs has been employed safely and effectively in children, adolescents and adults, its application in the small infant (weight <6 kg) carries a higher risk for complications including arrhythmias, hemodynamic compromise, cardiac perforation, tamponade and death. Perventricular closure of such defects, introduced by Amin and coworkers in the late 1990s, has become an attractive treatment modality for these small and high-risk patients. Experience worldwide has shown that the procedure is feasible, reproducible, safe and effective. In this article, the authors review the indications, the step-by-step technique and the results of perventricular closure of MVSDs using the AMPLATZER{\circledR} mVSD device (AGA Medical, MN, USA).",
keywords = "AMPLATZER, Hybrid, Interventional catheterization, Muscular ventricular septal defects, Perventricular",
author = "Pedra, {Carlos A.C.} and Pedra, {Simone R.F.} and Paulo Chaccur and Marcelo Jatene and Costa, {Rodrigo N.} and Hijazi, {Ziyad M.} and Zahid Amin",
year = "2010",
month = "5",
day = "1",
doi = "10.1586/erc.10.31",
language = "English (US)",
volume = "8",
pages = "663--674",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Perventricular device closure of congenital muscular ventricular septal defects

AU - Pedra, Carlos A.C.

AU - Pedra, Simone R.F.

AU - Chaccur, Paulo

AU - Jatene, Marcelo

AU - Costa, Rodrigo N.

AU - Hijazi, Ziyad M.

AU - Amin, Zahid

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Muscular ventricular septal defects (MVSDs) account for approximately 20% of all congenital ventricular septal defects. Large defects in infants result in early heart failure, failure to thrive and pulmonary hypertension. Although percutaneous closure of MVSDs has been employed safely and effectively in children, adolescents and adults, its application in the small infant (weight <6 kg) carries a higher risk for complications including arrhythmias, hemodynamic compromise, cardiac perforation, tamponade and death. Perventricular closure of such defects, introduced by Amin and coworkers in the late 1990s, has become an attractive treatment modality for these small and high-risk patients. Experience worldwide has shown that the procedure is feasible, reproducible, safe and effective. In this article, the authors review the indications, the step-by-step technique and the results of perventricular closure of MVSDs using the AMPLATZER® mVSD device (AGA Medical, MN, USA).

AB - Muscular ventricular septal defects (MVSDs) account for approximately 20% of all congenital ventricular septal defects. Large defects in infants result in early heart failure, failure to thrive and pulmonary hypertension. Although percutaneous closure of MVSDs has been employed safely and effectively in children, adolescents and adults, its application in the small infant (weight <6 kg) carries a higher risk for complications including arrhythmias, hemodynamic compromise, cardiac perforation, tamponade and death. Perventricular closure of such defects, introduced by Amin and coworkers in the late 1990s, has become an attractive treatment modality for these small and high-risk patients. Experience worldwide has shown that the procedure is feasible, reproducible, safe and effective. In this article, the authors review the indications, the step-by-step technique and the results of perventricular closure of MVSDs using the AMPLATZER® mVSD device (AGA Medical, MN, USA).

KW - AMPLATZER

KW - Hybrid

KW - Interventional catheterization

KW - Muscular ventricular septal defects

KW - Perventricular

UR - http://www.scopus.com/inward/record.url?scp=77952113644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952113644&partnerID=8YFLogxK

U2 - 10.1586/erc.10.31

DO - 10.1586/erc.10.31

M3 - Review article

VL - 8

SP - 663

EP - 674

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 5

ER -